Man Group plc Has $6.10 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Man Group plc boosted its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 182.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 157,963 shares of the company’s stock after purchasing an additional 102,132 shares during the period. Man Group plc owned about 0.27% of Protagonist Therapeutics worth $6,097,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of PTGX. Covestor Ltd grew its stake in shares of Protagonist Therapeutics by 5,200.0% in the 4th quarter. Covestor Ltd now owns 1,643 shares of the company’s stock valued at $63,000 after buying an additional 1,612 shares during the period. KBC Group NV grew its stake in shares of Protagonist Therapeutics by 54.4% in the 4th quarter. KBC Group NV now owns 2,093 shares of the company’s stock valued at $81,000 after buying an additional 737 shares during the period. New Vernon Capital Holdings II LLC acquired a new stake in shares of Protagonist Therapeutics in the 4th quarter valued at about $118,000. Nisa Investment Advisors LLC grew its stake in shares of Protagonist Therapeutics by 10.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company’s stock valued at $121,000 after buying an additional 295 shares during the period. Finally, Cibc World Markets Corp acquired a new stake in shares of Protagonist Therapeutics in the 4th quarter valued at about $211,000. 98.63% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director William D. Waddill sold 4,000 shares of Protagonist Therapeutics stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $54.25, for a total transaction of $217,000.00. Following the completion of the sale, the director now directly owns 13,130 shares in the company, valued at $712,302.50. This trade represents a 23.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Asif Ali sold 24,903 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $58.73, for a total transaction of $1,462,553.19. Following the sale, the chief financial officer now owns 62,821 shares in the company, valued at approximately $3,689,477.33. This trade represents a 28.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 61,173 shares of company stock valued at $3,461,180 in the last 90 days. Insiders own 4.90% of the company’s stock.

Protagonist Therapeutics Price Performance

Shares of NASDAQ PTGX opened at $46.61 on Wednesday. The stock has a market cap of $2.89 billion, a PE ratio of 17.52 and a beta of 2.65. The firm has a fifty day moving average price of $46.36 and a 200-day moving average price of $42.59. Protagonist Therapeutics, Inc. has a 1 year low of $27.00 and a 1 year high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.31. The business had revenue of $28.32 million during the quarter, compared to analyst estimates of $30.44 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. On average, research analysts expect that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Analysts Set New Price Targets

PTGX has been the topic of several recent research reports. Wedbush reaffirmed an “outperform” rating and issued a $70.00 price target on shares of Protagonist Therapeutics in a research report on Friday, March 28th. JMP Securities reaffirmed a “market outperform” rating and issued a $58.00 price target on shares of Protagonist Therapeutics in a research report on Friday, February 7th. BTIG Research set a $73.00 target price on shares of Protagonist Therapeutics in a research report on Monday, March 3rd. BMO Capital Markets lifted their target price on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 11th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $65.44.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.